癌症免疫疗法,包括免疫检查点抑制剂,引起长期临床反应,但许多癌症患者没有反应。因此,正在进行密集的努力以鉴定可以被调节以增强现有免疫疗法的功效的另外的免疫途径。蜂毒强烈刺激免疫系统,并作为辅助疗法用于治疗中国晚期肿瘤患者的癌痛。蜂毒含有几种变应原蛋白酶抑制剂和肽。它引发超敏反应;也就是说,它是一种免疫系统激动剂。针对肿瘤相关抗原的自发T细胞应答的产生需要先天免疫激活;这驱动I型干扰素的产生。我们报告了一名患有复发性和难治性脂肪肉瘤的患者,他经历了几次手术,化疗,和放射治疗。肿瘤很大。患者已达到最大辐射暴露剂量。肿瘤对化疗有抗性并浸润心包,肺,和隔膜。该患者不适合切除。因此,他接受了api疗法(蜂毒和针灸的组合)来控制疼痛;然后给予阿帕替尼(抗血管生成药物)以抑制肿瘤生长,但由于患者无法耐受副作用而被提前终止。随后,程序性死亡1抑制剂与api疗法联合使用.蜂毒可作为先天免疫系统激动剂,促进肿瘤微环境中的免疫细胞启动和募集。病人终于能够接受脂肪肉瘤的根治性切除术,术后16个月复查时没有发现复发的证据.
Cancer immunotherapies, including immune checkpoint inhibitors, elicit long-term clinical responses but many cancer patients do not respond. Intensive efforts are therefore underway to identify additional immune pathways that may be modulated to enhance the efficacy of existing immunotherapies. Bee venom strongly stimulates the immune system, and is used as a complementary therapy to treat cancer pain in patients with advanced tumors in China. Bee venom contains several allergenic protease inhibitors and peptides. It triggers hypersensitivity reactions; that is, it is an immune system agonist. The generation of a spontaneous T cell response against tumor-associated antigens requires innate immune activation; this drives type I interferon production. We report a patient with a relapsed and refractory liposarcoma who had undergone several operations, chemotherapies, and radiotherapies. The tumor was large. The patient had attained the maximum radiation exposure dose. The tumor was resistant to chemotherapy and was infiltrating the pericardium, lungs, and diaphragm. The patient was a poor candidate for resection. He thus received apitherapy (a combination of bee venom and acupuncture) to control pain; then apatinib (an anti-angiogenic drug) was given to inhibit tumor growth but was terminated early because the patient could not tolerate the side effects. Subsequently, a programmed death 1 inhibitor was combined with apitherapy. Bee venom served as an innate immune system agonist promoting immune cell priming and recruitment in the tumor microenvironment. The patient was finally able to undergo radical liposarcoma resection, and no evidence of recurrence was found at re-examination 16 months after surgery.